ABL Bio, a Korean biotech company, said it received 75 million (about 91 billion won) upfront payment from Sanofi as part of the licensing agreement for ABL301, an antibody targeting alpha-synuclein and IGF1R to treat degenerative brain diseases, including Parkinson's disease.In January, ABL Bio sig
Kolon TissueGene, which avoided delisting with a one-year grace period last year, is still facing the risk of delisting because of its financial instability.The Korea Exchange (KRX) said on Monday that it added one more reason to designate Kolon TissueGene as an administrative issue because the comp
TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2218 in a phase 1a study. The company enrolled the first patient in January. The patient enrollment and drug administrati
Medipost said that it started administering SMUP-IA-01, an injection type knee osteoarthritis treatment, in a phase 2 trial in Korea.The phase 2 trial follows a previous phase 1 clinical trial of SMUP-IA-01, where the company confirmed the safety and improvement of pain and joint function in 12 pati
Abion had said it completed patient enrollment for a phase 1 clinical trial of anticancer medicine. However, the ClinicalTrials.gov site recently showed that the study was still “recruiting” patients.According to the site, operated by the U.S. National Institutes of Health, Abion changed the status
CKD Bio said Thursday it signed a contract manufacturing organization (CMO) deal with EnhancedBio to produce ionizable lipids, a key substance in EN-LNP technology.EN-LNP is a lipid nanoparticle (LNP) platform to deliver gene therapy materials, including vaccines and treatments to cells. The technol
CHA Biotech released the topline results of the phase 1 clinical trial of CBT101, a natural killer (NK) cell therapy to treat solid cancer, on Thursday.CBT101 is experimental immunotherapy made by multiplying the patient’s NK cells that play a significant role in congenital immunity.CHA Biotech said
The Russian invasion of Ukraine might disrupt ongoing drug trials conducted by Korean biotech companies in Ukraine, industry watchers worried.However, Korean companies said their clinical trials in Ukraine were part of multinational ones, and the ongoing conflict would rarely affect global studies.C
GC said it has applied for product approval for Maralixibat, an Alagille syndrome (ALGS) treatment, to the Food and Drug Safety Ministry.ALGS is a rare genetic disease in children in which the hepatic biliary tract decreases and bile stagnates, and the only available treatment is currently liver tra
Seegene, a multiplex molecular diagnostics company, said Thursday that it has developed a diagnostic reagent that can identify the Covid-19 infection in 30 minutes.Seegene’s new product, Allplex SARS-CoV-2 fast MDx Assay, has obtained the Conformity European In-Vitro Diagnostics (CE-IVD) marking. Th
The International Vaccine Institute (IVI) said the Ministry of Health and Welfare had been named it to operate “2022 Global Bio-Intensive Training Courses,” a Korean government program.IVI will provide workforce training in vaccine and biologics R&D and manufacturing for people from low- and middle-
Biotech companies developing an mRNA-based Covid-19 vaccine are busy responding to the Omicron variant.They are conducting clinical trials of existing candidate vaccines and simultaneously studying their efficacy against virus variants.According to the Ministry of Food and Drug Safety’s data release
Aptamer Sciences said on Friday that it signed a CDMO (contract development and manufacturing organization) agreement with China’s Asymchem for developing an anticancer drug.The deal involves GMP process development and production of clinical samples of AST-201, an aptamer-drug conjugate (ApDC)-base
NeoImmuneTech said it released preclinical results of NT-I7 in mouse models of glioblastoma (GBM) in Clinical Cancer Research, a major oncology journal published by the American Association for Cancer Research (AACR).NeoImmuneTech is developing NT-I7 as a T cell amplifier immunotherapy.The preclinic
The Korea Exchange said it tentatively decided to delist Sillajen from the tech-heavy Kosdaq market. Following the KRX decision, the Kosdaq market committee will determine whether to delist the biotech firm.On Tuesday, the KRX held a meeting of the corporate review committee and said it would kick S
ImmuneOncia Therapeutics said on Monday that it raised 24.5 billion won ($20.5 million) pre-IPO funds.Earlier in 2019, the company attracted 45 billion won investment from Paratus Investment, a private-equity firm.Before going public, ImmuneOncia raised 70 billion won in total.Yuhan Corp., the large
Samsung Biologics said Thursday that it would secure a new driving force that will guide its future growth while strengthening competitiveness in the contract manufacturing organization (CMO) sector this year."We will expand our three growth pillars of production capacity, business portfolio, and gl
The financial regulator allowed Pharma Research Bio to resume stock trading from Thursday, about one month after the suspension of trading shares.On Wednesday, the Korea Exchange’s KONEX, an exchange exclusively for small- and medium-sized enterprises (SMEs), announced that it would exclude Pharma R
Celltrion and its affiliate Celltrion Healthcare said on Monday that their boards of directors decided to repurchase shares to stabilize stock prices.Celltrion plans to repurchase 547,946 shares worth 100 billion won (182,500 won per share).Celltrion Healthcare is to buy back 673,854 shares worth 50
SK is stepping up efforts to emerge as a global cell and gene therapy contract development and manufacturing organization (CDMO).The company said Sunday that it has become the second-largest shareholder of CBM, a U.S. CDMO specializing in cell and gene therapy, by investing $350 million (about 420 b
